Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151054 | 0.79 | SIGMAR1 (0.44) | OPRM1OPRD1MEN1KMT2A | |
| SCHEMBL18284750 | 0.77 | OPRM1 (0.39) | OPRM1OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL2226221 | 0.76 | OPRM1 (0.35) | OPRM1OPRD1OPRL1OPRK1SLC6A2 | |
| SCHEMBL4759637 | 0.75 | HTR2A (0.38) | OPRM1OPRD1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL27587006 | 0.74 | SIGMAR1 (0.36) | OPRM1OPRD1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL6371581 | 0.73 | MMP2 (0.38) | OPRM1OPRD1OPRL1OPRK1MEN1 | |
| SCHEMBL4592731 | 0.73 | SIGMAR1 (0.38) | OPRM1OPRD1MEN1KMT2ASLC6A2 | |
| SCHEMBL14698728 | 0.72 | SIGMAR1 (0.35) | OPRM1OPRD1OPRL1OPRK1MEN1 | |
| SCHEMBL3941026 | 0.71 | CHRNB2 (0.38) | — | |
| SCHEMBL3721247 | 0.70 | SIGMAR1 (0.39) | OPRM1OPRD1KMT2ASLC6A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | OPRM1 100/4885OPRD1 120/4885OPRL1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.